A GLP-1 agonist is a medication that mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1) to lower blood sugar, reduce appetite, and promote weight loss. Originally developed for type 2 diabetes, these drugs have become some of the most widely prescribed medications in the world, with newer versions now approved for obesity and cardiovascular risk reduction.
Your body produces GLP-1 naturally every time you eat. GLP-1 agonists work by delivering a longer-lasting, more potent version of that same signal, amplifying effects that your gut already initiates on its own.
How GLP-1 Agonists Work in the Body
When you eat, specialized cells in your intestines release GLP-1 into the bloodstream. This hormone travels to the pancreas, where it binds to receptors on insulin-producing cells and boosts insulin release in response to rising blood sugar. The key detail here is that this insulin boost is glucose-dependent: it only kicks in when blood sugar is elevated, which is why GLP-1 agonists carry a much lower risk of causing dangerously low blood sugar compared to some older diabetes medications.
GLP-1 also suppresses glucagon, a hormone that tells your liver to release stored sugar. By dialing down glucagon while dialing up insulin, these drugs improve the overall balance between the two hormones, making the body more sensitive to insulin overall.
Beyond the pancreas, GLP-1 agonists slow gastric emptying, meaning food stays in your stomach longer. This contributes to feeling full after smaller meals, though it’s also one reason these drugs commonly cause nausea, especially when first starting treatment.
The effects on appetite go deeper than just a full stomach. GLP-1 receptors are found in brain regions that control hunger. When activated, these receptors increase the production of chemicals that suppress appetite while simultaneously decreasing the signals that drive you to eat. This combination of gut-level fullness and brain-level appetite suppression is what makes GLP-1 agonists so effective for weight loss. Research has also shown that the satiety signal from GLP-1 in the gut travels to the brain via the vagus nerve, creating a two-pronged system: direct action on the brain plus indirect signaling from the digestive tract.
Available Medications
The first GLP-1 agonist, exenatide (Byetta), was approved in 2005 and required twice-daily injections. Since then, the class has evolved considerably. Most current options are once-weekly injections, and one is available as a daily oral tablet.
The GLP-1 agonists currently on the U.S. market include:
- Exenatide (Byetta, Bydureon): the original, available as twice-daily or extended-release weekly injection
- Liraglutide (Victoza for diabetes, Saxenda for weight management): once-daily injection
- Dulaglutide (Trulicity): once-weekly injection
- Lixisenatide (Adlyxin): once-daily injection
- Semaglutide (Ozempic for diabetes, Wegovy for weight management): once-weekly injection, also available as a daily oral tablet (Rybelsus) for diabetes
Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is closely related but technically a dual agonist. It activates both the GLP-1 receptor and a second gut hormone receptor called GIP, which may explain why it produces even greater effects on weight and blood sugar in head-to-head comparisons.
What They’re Approved to Treat
GLP-1 agonists have three primary areas of FDA-approved use. The first and most established is type 2 diabetes, where they lower blood sugar and, in some cases, reduce the risk of heart attack and stroke. The second is chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Semaglutide (Wegovy) received this approval in 2021, and tirzepatide (Zepbound) followed in 2023.
Cardiovascular protection is the third area. In the SELECT trial, semaglutide reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in people with obesity and established heart disease who did not have diabetes. A major 2024 trial published in the New England Journal of Medicine also demonstrated that semaglutide reduced the risk of serious kidney events by 24% in people with type 2 diabetes and chronic kidney disease, slowing the rate of kidney function decline over a median follow-up of 3.4 years.
Weight Loss Results
The weight loss achieved with GLP-1 agonists is substantially greater than what older anti-obesity medications could deliver. In a head-to-head trial comparing the two leading options over 72 weeks, tirzepatide produced an average weight reduction of 20.2%, while semaglutide produced 13.7%. Longer-term data shows even larger effects: up to 22.9% body weight loss with tirzepatide after nearly 3.5 years of treatment, and 16.7% with semaglutide after about 2 years.
For context, a person weighing 250 pounds could expect to lose roughly 34 to 50 pounds on semaglutide and 50 to 57 pounds on tirzepatide, depending on the timeframe and dose. These are averages, and individual results vary. The weight loss is not permanent if the medication is stopped; most people regain a significant portion of the lost weight, which is why these drugs are generally considered long-term treatments rather than short courses.
How They’re Taken
Most GLP-1 agonists are injected under the skin using a prefilled pen, similar to an insulin pen but with a very small needle. The injection can go into the abdomen, thigh, or upper arm, and the once-weekly versions can be taken on any day at any time, with or without food.
All GLP-1 agonists start at a low dose and gradually increase over several weeks, a process called titration. This slow ramp-up is designed to let your digestive system adjust and reduce the severity of side effects. Semaglutide injections, for example, start at 0.25 mg weekly, increase to 0.5 mg after four weeks, and can eventually reach 1 mg or 2 mg depending on the treatment goal. Tirzepatide starts at 2.5 mg weekly and increases in 2.5 mg steps every four weeks, up to a maximum of 15 mg.
Oral semaglutide (Rybelsus) is the one pill option currently available, approved for type 2 diabetes. It must be taken on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before eating, drinking anything else, or taking other medications. This specific routine is necessary because the tablet includes an absorption enhancer that only works under these conditions.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent side effects. Nausea affects up to 50% of people starting a GLP-1 agonist, making it the single most common complaint. Diarrhea is also very common, occurring in at least 1 in 10 users. Vomiting, constipation, abdominal pain, and indigestion are somewhat less frequent but still reported regularly.
These side effects are usually worst during the first few weeks at each new dose level and tend to improve over time as the body adjusts. The gradual dose titration schedule exists specifically to minimize these effects, and most people find them manageable enough to continue treatment. Eating smaller meals, avoiding high-fat foods, and eating slowly can help.
Pancreatitis has been a concern since these drugs first came to market. Pooled data from clinical trials shows a slightly elevated rate of pancreatitis in people taking GLP-1 agonists compared to other treatments, but the difference is not statistically significant. Still, persistent severe abdominal pain that radiates to the back warrants prompt medical attention.
All GLP-1 agonists carry an FDA black box warning related to thyroid tumors. In rodent studies, these drugs caused overgrowth of thyroid C-cells, which can progress to medullary thyroid carcinoma. A large 2025 study in people with type 2 diabetes found no increased risk of thyroid cancer with long-term GLP-1 agonist use, but the drugs remain contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called multiple endocrine neoplasia type 2 (MEN2).
Next-Generation GLP-1 Treatments
The current wave of GLP-1 agonists may soon be joined by oral versions that don’t require the strict dosing routine of Rybelsus. Orforglipron, a small-molecule GLP-1 agonist in pill form, is expected to seek FDA approval in 2026 and could make these treatments far more accessible for people who prefer not to inject. Retatrutide, a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously, has shown average weight loss of up to 28.7% in clinical trials and is also heading toward regulatory submission. Amycretin, an oral dual agonist targeting both GLP-1 and amylin pathways, showed 13% weight loss in early-stage trials, signaling that effective oral options with multiple mechanisms are on the horizon.